Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.87% | |
| Gapped Down | Weakness | 0.87% | |
| Oversold Stochastic | Weakness | 0.87% | |
| 180 Bearish Setup | Bearish Swing Setup | -0.60% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.60% | |
| NR7 | Range Contraction | -0.60% | |
| Wide Bands | Range Expansion | -0.60% | |
| Oversold Stochastic | Weakness | -0.60% | |
| Wide Bands | Range Expansion | -1.85% |
| Alert | Time |
|---|---|
| Up 2% | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Rose Above 10 DMA | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| Down 1% | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Iovance Biotherapeutics, Inc. Description
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Oncology Cancer Immunotherapy Cell Therapy Melanoma Antineoplastic Drugs Cancer Cell Lymphocytes Checkpoint Inhibitor Adoptive Cell Transfer Head And Neck Cancer Immunotherapy Products National Cancer Institute Cancer Immunotherapy Product Metastatic Melanoma Pembrolizumab Tumor Infiltrating Lymphocytes Breast And Lung Cancer Ocular Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.33 |
| 52 Week Low | 3.21 |
| Average Volume | 9,724,993 |
| 200-Day Moving Average | 8.24 |
| 50-Day Moving Average | 13.99 |
| 20-Day Moving Average | 12.51 |
| 10-Day Moving Average | 11.67 |
| Average True Range | 0.74 |
| RSI (14) | 39.02 |
| ADX | 21.06 |
| +DI | 16.66 |
| -DI | 27.21 |
| Chandelier Exit (Long, 3 ATRs) | 12.97 |
| Chandelier Exit (Short, 3 ATRs) | 13.22 |
| Upper Bollinger Bands | 14.39 |
| Lower Bollinger Band | 10.63 |
| Percent B (%b) | 0.27 |
| BandWidth | 30.05 |
| MACD Line | -0.63 |
| MACD Signal Line | -0.56 |
| MACD Histogram | -0.0719 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.34 | ||||
| Resistance 3 (R3) | 12.31 | 12.06 | 12.22 | ||
| Resistance 2 (R2) | 12.06 | 11.88 | 12.07 | 12.18 | |
| Resistance 1 (R1) | 11.85 | 11.77 | 11.95 | 11.87 | 12.14 |
| Pivot Point | 11.59 | 11.59 | 11.64 | 11.60 | 11.59 |
| Support 1 (S1) | 11.38 | 11.41 | 11.49 | 11.41 | 11.14 |
| Support 2 (S2) | 11.13 | 11.30 | 11.14 | 11.10 | |
| Support 3 (S3) | 10.92 | 11.13 | 11.06 | ||
| Support 4 (S4) | 10.94 |
